The medical marijuana industry is once again seeing positive strides as the DEA approves MMJ International Holdings' request to import proprietary cannabis extracts into the United States.

It has been a difficult road for those in the medical marijuana industry to convenience the general population and legislation about cannabis’ medicinal purposes. As the years have continued, companies such as MMJ International Holdings continue to fight the good fight and pave the way toward cannabis’ acceptance in the medical industry.

The DEA has approved MMJ International Holdings’ permit to import its proprietary cannabis extracts into the US. These extracts will be used to develop treatments for Huntington’s Disease and Multiple Sclerosis. Currently, no THC (tetrahydrocannabinol) or CBD (cannabidiol) products are proven to treat the symptoms of these conditions.

It has been a lengthy process for MMJ International Holdings to get to this point. It was not until early in 2019 that the FDA approved MMJ International Holdings’ request to assign the Huntington’s orphan drug the designation it needed in order to advance the therapy. Just recently, the Center for Drug Evaluation and Research (CDER) gave its approval for MMJ International Holdings to develop its gel cap that will be used to deliver the THC (tetrahydrocannabinol) and CBD (cannabidiol) extracts.

With these milestones finally achieved, the company can continue to advance their therapies and work toward their final goal: create a safe, FDA approved cannabis drug to treat symptoms of Huntington’s disease and multiple sclerosis.

The proprietary imported cannabis extracts, MMJ-001 and MMJ-002, are formulations of liquid THC, CBD, and other active ingredients. Each extract has its own unique benefits and will treat separate symptoms. MMJ-001 is being developed to treat multiple sclerosis patients suffering from abnormal muscle stiffness (spasticity). MMJ-002 is being developed to treat involuntary movements, jerking, and writhing in those who suffer from Huntington’s disease (chorea).

The gel cap being developed by MMJ International Holdings is being fully derived from the entire cannabis plant. Combined with the power of the proprietary extracts, the executives of the company are confident they can deliver a drug that will effectively treat the symptoms of Huntington’s disease and multiple sclerosis and allow users to enjoy life better each day.

MMJ International Holdings still has quite a way to go before the drug can be sold on the market. The company has been working tirelessly since 2015 to move forward with these therapies. However, a well-deserved victory can be celebrated for clearing numerous legal hurdles and earning the cooperation of the FDA, DEA, CBP, and CDER.

Medical marijuana is already approved by the FDA for use to treat a number of conditions and symptoms. If you suffer from any qualifying conditions in Ohio, it is incredibly easy to qualify for your MMJ card. Simply find the location nearest you and complete the intake process. If you pre-qualify, you can skip the waiting room! From there, you will have a face-to-face examination with a licensed physician who is certified to recommend MMJ cards. It’s truly that simple! Please contact us today if you have any questions.